secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2026-04-20T23:59:59+00:00
Accession:  0001193125-26-162620
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Prelude Therapeutics presents preclinical data for PRT13722 KAT6A degrader at AACR 2026, plans IND mid-2026
--------------------------------------------------------------------------------

- PRT13722 is a first-in-class, orally bioavailable, potent and highly selective KAT6A degrader for HR+/HER2- breast cancer.
- Preclinical data show durable complete tumor regressions in xenograft models at well-tolerated doses as monotherapy.
- PRT13722 demonstrated improved preclinical hematological safety profile compared to prifetrastat.
- PRT13722 showed synergistic activity with endocrine therapy, CDK4/6 inhibitors, and PI3Kα inhibitors.
- IND filing expected in mid-2026; Phase 1 study initiation planned for second half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526162620/0001193125-26-162620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526162620/d135229d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-162620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer